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Abstract: Because of the severe complications that may result from
varicella zoster virus (VZV) infection following renal transplantation
(Tx), transplanted varicella-susceptible children exposed to varicella are
typically given varicella zoster immunoglobulin (VZIG) as prophylaxis
or are admitted and treated with parenteral acyclovir if VZIG
prophylaxis fails. As both VZIG and hospitalization are costly,
prevention of varicella infection by vaccination could potentially result
in signi®cant cost savings in addition to decreasing morbidity and
mortality. To test this hypothesis, we developed a decision-analysis
model to evaluate the cost-effectiveness of vaccinating patients with
chronic renal failure (CRF) against varicella prior to renal transplant.
Under baseline assumptions, vaccination for varicella pretransplant was
a cost-effective strategy, with a cost of $211 per patient vaccinated
compared with $1,828 per patient not vaccinated. The magnitude of cost
savings from vaccination was sensitive to variations in the cost of
varicella vaccine, the percentage of patients hospitalized for treatment
with acyclovir, and the percentage of patients exposed to varicella
infection. One- and two-way sensitivity analyses con®rmed that
vaccination was the dominant cost-effective strategy under all conditions
examined. We conclude that vaccination for varicella pretransplant is
cost-effective for patients with CRF, and that the magnitude of cost
savings is sensitive to the cost of hospitalization, the percentage of
patients exposed to varicella, and the cost of varicella vaccination.
Pending results of ongoing studies of the safety and ef®cacy of VZV
vaccine in children with CRF, we recommend that VZV vaccine be given
to all children with CRF.
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Varicella infection post-renal Tx may cause severe
complications, including allograft rejection, hepa-
titis, pneumonitis, or death (1±12). Transplant
recipients exposed to varicella are generally
treated with VZIG in an attempt to prevent
actual infection (13±16). Hospitalization for
treatment with i.v. acyclovir is generally required
in patients who develop varicella infection, despite
VZIG prophylaxis, in order to decrease viral
replication and prevent severe complications (4, 6,
10, 13, 17±19). Varicella vaccination offers the
possibility of decreasing the number of patients
with varicella infection, and/or ameliorating the
course of varicella infection, thereby preventing or
reducing the costs associated with the usual
approaches mentioned above (9, 10, 14, 20±27).
We hypothesized that prior to Tx, vaccination
of all children with CRF who are susceptible to
varicella infection is a cost-effective approach,
resulting in decreased costs and improved out-
comes, including decreased rates of hospital
admissions, decreased requirements for VZIG
prophylaxis, and a lower probability of death
Abbreviations: CMV, cytomegalovirus; CRF, chronic renal failure;
EBV, Epstein±Barr virus; i.v., intravenous; NACHRI, National
Association of Childrens' Hospitals and Related Institutions; Tx,
transplantation; VZV, varicella zoster virus; VZIG, varicella zoster
immunoglobulin.
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from varicella infection. In order to examine this
hypothesis, we carried out a cost-analysis study,
comparing the cost of universal screening by
history and vaccination of VZV-negative patients
with the standard treatments of VZIG adminis-
tration post-exposure and hospitalization for
treatment with i.v. acyclovir.
Methods
Decision tree
For this study we developed a decision-analysis
tree using a decision-modeling program (Data 3.0;
TreeAge, Inc., Cambridge, MA, USA). Our
model compared two strategies: strategy 1
involved immunization of children with CRF
against varicella prior to renal Tx; and strategy 2
involved no immunization. In strategy 2 (no
immunization), non-VZV immune transplant
recipients exposed to varicella were given VZIG
for prophylaxis, and were hospitalized for treat-
ment with parenteral acyclovir if active varicella
infection developed despite prophylaxis.
Baseline assumptions and ranges for sensitivity
analysis were obtained from a review of the liter-
ature, expert opinions, an estimate of costs of care
at comparable Children's Hospitals, and clinical
experience at the University of Michigan, and are
outlined in Tables 1 and 2. Costs of the two-dose
varicella vaccination program, VZIG administra-
tion, and hospitalization for i.v. acyclovir used in
this model, were based upon costs reported in a
national database generated by the NACHRI.
Only patients without a prior history of varicella
infection or vaccination were included in the
model. A two-dose varicella vaccination program
was chosen to ensure an optimal immune response
in this immune-compromised population. The
costs indicated in our baseline assumptions
included all direct medical costs. For example,
cost of immunization included the cost of two
doses of vaccine, the cost of a visit, and the cost of
vaccine administration.
The decision tree evaluated sequentially the
impact of vaccination or lack of vaccination on:
1 the cost of treatment;
2 the use of VZIG;
3 the frequency of infection with varicella
virus;
4 the number of hospital admissions; and
5 the number of deaths from varicella com-
plications.
The frequency of infection was determined by
the exposure rate to varicella, the risk of acquiring
infection once exposed, the impact of receiving
VZIG on the risk of infection, the risk of hospit-
alization as a result of infection, and the risk of
death and allograft rejection from complications
of varicella infection. In our model, we presumed
that the risk of acquiring varicella infection once
exposed was 0.5, mid-range between the reported
risk of acquiring infection for household expo-
sures, which was as high as 0.85, and the risk
following a classroom exposure of 0.2 (28). The
risk of exposure of 0.223 per year therefore
resulted in a risk of infection of 0.111 per year.
The risk of exposure of 0.223 was chosen so that
the risk of infection rate approximated the
average seroconversion rate of 11% per year
reported in children aged 2±7 yr (28, 29). With a
risk of infection with varicella of 11% per year up
to 7 yr of age, our model predicts that 45% of
children would acquire varicella over the 5 yr
modeled period, compared with the reported
acqusition rate of 55% for children aged 2±7 yr
(28±31).
For this analysis, all costs were discounted at
5% per year. Therefore, costs in the ®rst year were
assigned full value, while costs in subsequent
years were discounted at an annual rate of 5% per
year. It is a necessary and standard procedure to
discount costs and savings that will occur in the
future to adjust for the greater bene®t of having a
Table 1. Probability assumptions used in the decision tree
Event Baseline Worst case Range References/source of data
Exposure to varicella per year 0.223 0.16 0.16±0.248 (28)
Varicella infection per year 0.111 0.08 0.08±0.124 (28)
Protection by varicella 0.950 0.83 0.83±0.950 (29)
Recognizing exposure to varicella 0.800 0.95 0.70±0.950 *{
Receiving VZIG once exposed 0.900 0.95 0.50±0.950 *{
Recognized protection by VZIG 0.900 0.95 0.50±0.950 { (39)
Sub-clinical infection 0.060 0.10 0.04±0.150 (31, 30)
Probabilities are indicted as a decimal and represent probability per year.
* Expert opinion of transplant coordinators from Bone Marrow, Renal and Liver transplant services at the University of Michigan Medical Center.
{ Expert opinion of a Pediatric Infectious Disease Physician Panel at the University of Michigan Medical Center.
VZIG, varicella zoster immune globulin.
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resource (i.e. dollars to spend) today rather than
at a future time.
To test the sensitivity of our analysis to changes
in our assumptions, we examined the effect of
varying our assumptions over a range of values
indicated in Tables 2 and 3. In a `one-way
sensitivity analysis' each assumption was varied
over the range indicated graphed on the x-axis and
the effect on the cost of care under each analysis
was noted on the y-axis. In a `two-way sensitivity
analysis' two assumptions were varied over the
ranges simultaneously, and the most cost-effective
strategy for each pair of inputs was determined.
Results
Cost savings from vaccination
Under our baseline assumptions, vaccination
against varicella was the dominant cost-effective
strategy, with a cost of $211 per child vaccinated
compared with $1,828 per child not vaccinated
(Fig. 1). Therefore for each dollar spent on the
vaccination strategy, more than $8 would be
saved on avoided treatment costs.
In the immunization strategy, the major cost
arose from primary prevention (varicella vacci-
nation), while in the no-immunization strategy
the greatest costs arose from secondary preven-
tion (VZIG following exposure) and treatment
(hospitalization for acyclovir following onset of
varicella) (Fig. 2). The lower risk of varicella
infection in the immunization strategy led to
substantial savings from decreased hospital
admissions and fewer patients requiring VZIG.
These savings were considerably greater than the
added cost of immunization (Fig. 2).
The likelihood of receiving VZIG was signi®-
cantly greater under the no-immunization strat-
egy (64.8%) than under the immunization
strategy (0%) (Table 3). The number of patients
requiring hospitalization for treatment with i.v.
acyclovir because of active varicella infection
under the immunization strategy (2.2%) was
considerably less than under the no-immuniza-
tion strategy (42.3%).
Sensitivity analysis
The magnitude of cost savings from vaccination
was sensitive to several variables, including:
N the cost of varicella vaccine;
N the percentage of patients exposed to varicella
infection;
N the number of patients who successfully
received and responded to VZIG with protection
against varicella infection; and
N the percentage of patients hospitalized for treat-
ment with acyclovir.
The cost saving (the difference in cost per case
under the no-immunization strategy vs. the immu-
nization strategy) rose as the cost of hospitaliza-
tion increased (Fig. 3), as the rate of exposure to
varicella increased (Fig. 4), and as the rate of
protection from varicella vaccination increased
(information not shown). The cost savings fell as
the cost of vaccination increased (Fig. 5), the
number of patients receiving VZIG increased
(information not shown) and the ef®cacy of VZIG
increased (information not shown). Although the
magnitude of savings varied, the immunization
strategy remained as a cost saving for all values
considered. In addition, sensitivity analyses,
changing both individual variables and multiple
Table 2. Cost assumptions
Costs Baseline Worst case Range Source of data
Cost of immunization $120 $200 $90±200 *{
Cost of VZIG treatment $450 $400 $400±600 *{
Cost of hospital admission for acyclovir treatment $7,200 $5,200 $5,200±7,200 *{
Costs are expressed in US dollars and represent the cost per episode of treatment.
* Cost estimates from the University of Michigan.
{ Cost estimates from NACHRI Pediatric Hospital Cost Data.
VZIG, varicella zoster immune globulin.
Table 3. Outcomes under baseline assumptions
Outcomes Immunized Non-immunized
Cost per patient $250 $2,700
Probability of receiving VZIG 0.0% 64.8%
Probability of infection 2.8% 45.0%
Probability of hospitalization for acyclovir treatment 2.2% 42.3%
Cost per patient and probabilities are indicated as the cost and chances for each patient.
Olson et al.
46
variables throughout the ranges indicated in
Tables 2 and 3, con®rmed that vaccination
remained the dominant cost-effective strategy
under all conditions examined.
To illustrate the robust nature of our conclu-
sion that vaccination for varicella is a cost saving,
we developed a `worst case' scenario where all the
assumptions were chosen to prejudice the analysis
against the varicella vaccination strategy. These
assumptions were:
N ef®cacy of varicella vaccine of only 83%;
N probability of exposure to varicella of 16% per
year;
N recognition of varicella of 95%;
N receipt of VZIG of 95%;
N 95% effectiveness of VZIG;
N cost of vaccination of $200; and
N cost of hospitalization of $5,200.
Even if all of these extreme conditions occured
(all of which are prejudicial to the cost-effective-
ness of the immunization strategy), varicella
vaccination remained the most cost-effective
strategy, with a cost of $300 compared to a cost
of no vaccinations of $588 (Fig. 1). Therefore,
even under these highly unlikely conditions, for
each dollar spent on varicella vaccination, almost
$2 would be saved on subsequent treatment costs.
Discussion
Following solid-organ Tx, viral infections remain
an important source of morbidity in both children
and adults, with the risk of most herpesvirus
infections, in particular, beginning < 4±6 weeks
post-Tx and continuing for the life of the trans-
plant recipient (32). The risk of acquiring such
infections is affected by the recipient's prior
exposure to the virus and their overall state of
immunosuppression, with recipients who have
required increased amounts of immunosuppres-
sion because of rejection probably having an
increased susceptibility for more severe disease
























Fig. 1. Cost-effectiveness of vaccination. Cost per case under
our baseline assumptions was signi®cantly less ($211) than
under the no-vaccination strategy ($1,828). Under our worst
case, assumptions were chosen to limit the cost-effectiveness
of the vaccination strategy ($300), as compared to the no-
vaccination strategy ($588).



















Fig. 2. Distribution of costs under the baseline assumptions.
Under our baseline assumptions, the no-immunization
strategy costs arose from hospitalization for treatment
with acyclovir and varicella zoster immune globulin
(VZIG) following exposure to varicella, and the
immunization strategy cost arose predominantly from the
cost of immunization.
immunization
























Cost of hospitalization for acyclovir (US $)
Fig. 3. Sensitivity analysis on the cost of hospitalization for
treatment with acyclovir. As the cost for hospitalization for
acyclovir increased, the cost of the no-immunization strategy
rose, increasing the potential cost saving using the
immunization strategy.
immunization























Probability of exposure to varicella (%)
Fig. 4. Sensitivity analysis on probability of exposure to
varicella. As the probability of exposure increased, the cost
per case for the no-immunization strategy increased, raising
the cost savings of the immunization strategy.
Pretransplant varicella vaccine in children
47
compared to recipients without a history of
rejection (33). For children, herpesvirus infections
such as CMV, EBV, and VZV are of particular
concern as many children will undergo Tx before
they have been exposed to these agents (19, 34,
35).
The complications of varicella infection post-
renal Tx are well-documented, and include dissem-
inated infection, acute renal failure, rejection, graft
loss, and death (1±13, 19). Such complications may
develop even with appropriate management using
post-exposure VZIG prophylaxis, treatment
with i.v. or oral acyclovir, and modi®cation of
immunosuppression (6, 9, 10, 19). Healthcare costs
associated with post-transplant varicella infection
can be substantial whether or not severe complica-
tions occur ± the cost of administration of VZIG,
which usually prevents the development of var-
icella infection (15, 16), can be as high as $450 per
treatment course. The costs of hospitalization are
also high, at up to $7,200 per admission.
Vaccination against varicella offers a potential
strategy of not only preventing the morbidity
associated with varicella infection, but also
reducing healthcare costs (36). Varicella vaccine
was licensed for use in the United States in March
1995, and since that time has been incorporated
into the routine schedule of immunizations
recommended by the Advisory Committee on
Immunization Practices (27), American Academy
of Pediatrics, Committee on Infectious Diseases
(37), and other consensus bodies. Although the
vaccine is generally well tolerated and quite
effective, it has not been universally adopted by
pediatricians and other primary care providers
(38), which means that many children with CRF
may not be immune to varicella when they are
referred to Pediatric Nephrologists for dialysis or
Tx. As the vaccine has been demonstrated to be
safe and effective in children with CRF (9, 21, 25),
the opportunity exists to ensure that such children
are varicella immune by the time they come to
transplant (14, 20, 26). Given that prior studies in
children with renal transplants (22), as well as the
early results of the Southwest Pediatric Nephro-
logy Study Group Varivax1 study (A. Furth,
personal communication), have indicated that
immunity to varicella will persist post-Tx, ensur-
ing pretransplant immunity would appear to be an
appropriate strategy for protection against post-
transplant VZV infection.
In this study, we conducted a cost analysis of
universal varicella vaccination of children with
CRF prior to renal Tx in order to determine
the cost ef®cacy of this practice. Although
multiple assumptions were required in develop-
ing this model, our analysis demonstrated that
varicella vaccination was the dominant strategy
under all conditions anticipated, even under a
worst-case scenario of decreased vaccine ef®-
cacy and low varicella exposure rates. Although
the magnitude of cost savings was sensitive to
the cost of hospitalization, the number of
patients exposed to varicella virus, and the
cost of varicella virus vaccination, vaccination
was always the dominant cost-effective strategy,
with savings ranging from $2 to greater than $8
per dollar spent on immunizations.
Given that the rate of varicella infection in
non-immunized individuals is as high as 20
times that in immunized individuals (40, 43),
and that varicella introduces the risk of graft
rejection, a higher rate of graft rejection could
be expected in non-immunized individuals.
Widespread vaccination against VZV will
potentially reduce the rate of infection and
thus the rate of rejection, resulting in further
cost savings as a result of decreased hospitali-
zation and decreased use of expensive anti-
rejection medications. If we had included these
potential savings in our model, the immuniza-
tion strategy would have shown even greater
savings when compared with the no-immuniza-
tion strategy.
We conclude that vaccination against var-
icella during the pretransplant period is cost-
effective for children with CRF. Our ®nding of
the cost savings combined with the decreased
risks of severe infection, graft rejection and
other complications of post-transplant varicella
add further weight to the call for complete
vaccination of this population against varicella
immunization

























Cost of immunization for varicella (US $)
Fig. 5. Sensitivity analysis on the cost of immunization for
varicella. As the cost of varicella vaccine rose, the cost per
case under the immunization strategy rose slightly,




(26). Based on this analysis, we recommend that
varicella vaccine be given to all children with
chronic renal failure prior to Tx.
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